BioToxTech Co

BioToxTech Co Financing Cash Flow

The Net Financing Cash Flow of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 762.48 M KRW. In the previous year, Net Financing Cash Flow was 33.02 B KRW — a change of -97.69% (lower).

Financing Cash Flow

762.48 MKRW

YoY

-97.69%

Last updated:

Net Financing Cash Flow of BioToxTech Co is 2024 762.48 M KRW. Net Financing Cash Flow of BioToxTech Co was 2023 33.02 B KRW. It decreases by -97.69% lower compared to the previous year.

The BioToxTech Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
2.17 B KRW
Jan 1, 2018
1.74 B KRW
Jan 1, 2019
567.86 M KRW
Jan 1, 2020
-141.21 M KRW
Jan 1, 2021
19.28 B KRW
Jan 1, 2022
21.93 B KRW
Jan 1, 2023
33.02 B KRW
Jan 1, 2024
762.48 M KRW
The BioToxTech Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
762.48 MKRW-97.69%
33.02 BKRW+50.59%
21.93 BKRW+13.75%
19.28 BKRW-13,753.01%
-141.21 MKRW-124.87%
567.86 MKRW-67.33%
1.74 BKRW-19.75%
2.17 BKRW-1,053.98%
-227.04 MKRW-62.90%
-611.88 MKRW-109.66%
6.33 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Net Financing Cash Flow of BioToxTech Co is 762.48 M KRW in 2024.

Net Financing Cash Flow of BioToxTech Co changed from 33.02 B KRW to 762.48 M KRW, representing a -97.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioToxTech Co

All Key Metrics — BioToxTech Co